Development and Regulatory Milestone Payments for a Product. For each milestone event set forth in Table 1 and Table 2 of this Section 4.2, ATI shall pay Rigel the corresponding non-refundable, non-creditable amount indicated for that milestone event for the first instance of its achievement: 1) [***] $ [***] 2) [***] $ [***] 3) [***] $ [***] 4) [***] $ [***] 5) [***] $ [***] 6) [***] $ [***]
Appears in 2 contracts
Sources: License and Collaboration Agreement (Aclaris Therapeutics, Inc.), License and Collaboration Agreement (Aclaris Therapeutics, Inc.)